MedTrace Logo

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

NCT03777059 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 910

Last updated 2021-07-09

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.

Conditions

  • Episodic Migraine

Interventions

DRUG

Atogepant

Atogepant tablet

DRUG

Placebo

Placebo-matching atogepant tablets

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Joel Trugman, MD · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-14
Primary Completion
2020-06-19
Completion
2020-06-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03777059 on ClinicalTrials.gov